{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:29:12Z","timestamp":1788226152832,"version":"build-2803163510"},"reference-count":59,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Placebo effects contribute substantially to the therapeutic success of many treatments, particularly in pain-related conditions. Open-label placebos (OLPs) offer an ethically acceptable approach to harness this potential without deception.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy of a 3-month OLP regimen in reducing headache and migraine days and improving migraine-related outcomes, including medication use, disability, and quality of life, in patients with migraine.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Patients<\/jats:title>\n This controlled, bicenter, parallel-group randomized clinical trial, with a 3-month treatment phase, enrolled adults with episodic or chronic migraine between November 9, 2020, and November 1, 2022. The trial was conducted at 2 tertiary headache centers in Germany (University Medicine Essen and Headache Center Frankfurt).<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants received OLPs plus treatment as usual (TAU) or TAU alone. OLPs were administered twice daily for 3 months.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The preregistered primary outcome was the change in monthly headache days from a baseline to a test period after 3 months. Secondary outcomes included patient-reported quality of life assessed using the 12-Item Short-Form Health Survey physical component summary, pain-related disability assessed using the Pain Disability Index and Headache Impact Test, and global improvement.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 120 patients (median age, 34.2 years; 95% CI, 29.8-39.3 years; 103 [86%] female), 102 (85%) had episodic migraine, and 18 (15%) had chronic migraine. All participants completed the study. Headache days did not significantly decrease in the OLP group compared with TAU. Similarly, there was no difference in the number of migraine days, pain intensity, days of rescue medication, and the 50% responder rate. However, OLP-treated patients reported improved quality of life (\u03b2\u2009=\u20094.25; 95% CI, 1.33-7.17;\n d<\/jats:italic>\n \u2009=\u20090.47;\n P<\/jats:italic>\n \u2009=\u2009.01), reduced pain-related disability (Pain Disability Index: \u03b2\u2009=\u2009\u22125.96; 95% CI, \u22129.01 to \u22122.92;\n d<\/jats:italic>\n \u2009=\u20090.53;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001; Headache Impact Test 6: \u03b2\u2009=\u2009\u22121.88; 95% CI, \u22123.28 to \u22120.48;\n d<\/jats:italic>\n \u2009=\u20090.35;\n P<\/jats:italic>\n \u2009=\u2009.02), and higher global improvement (\u03c7\n 2<\/jats:sup>\n \u2009=\u200914.16;\n P<\/jats:italic>\n \u2009=\u2009.01) compared with TAU patients.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, OLP treatment did not reduce headache frequency but was associated with improvements in quality of life and pain-related disability. Future research should clarify the mechanisms underlying these effects and determine their potential supportive role in migraine care for selected patients.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n drks.de identifier:\n DRKS00021259<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.35739","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:00:37Z","timestamp":1759935637000},"page":"e2535739","source":"Crossref","is-referenced-by-count":4,"title":["Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine"],"prefix":"10.1001","volume":"8","author":[{"given":"Julian","family":"Kleine-Borgmann","sequence":"first","affiliation":[{"name":"Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Schulz","sequence":"additional","affiliation":[{"name":"Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle-Lee","sequence":"additional","affiliation":[{"name":"Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[{"name":"Headache Center Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bingel","sequence":"additional","affiliation":[{"name":"Center for Translational Neuro- and Behavioral Sciences, Department of Neurology, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"10440","key":"zoi250999r1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","author":"Ferrari","year":"2024","journal-title":"Lancet"},{"issue":"10283","key":"zoi250999r2","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(20)32160-7","article-title":"Migraine: epidemiology and systems of care.","volume":"397","author":"Ashina","year":"2021","journal-title":"Lancet"},{"key":"zoi250999r3","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658","author":"Olesen","year":"2013","journal-title":"Cephalalgia"},{"issue":"4","key":"zoi250999r4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update.","volume":"64","author":"Charles","year":"2024","journal-title":"Headache"},{"issue":"2","key":"zoi250999r5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1212\/CON.0000000000001418","article-title":"Preventive Treatment of Migraine.","volume":"30","author":"Lipton","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"issue":"17","key":"zoi250999r6","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.","volume":"78","author":"Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"9","key":"zoi250999r7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","article-title":"EFNS guideline on the drug treatment of migraine\u2013revised report of an EFNS task force.","volume":"16","author":"Evers","year":"2009","journal-title":"Eur J Neurol"},{"issue":"4","key":"zoi250999r8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJMra010917","article-title":"Migraine\u2013current understanding and treatment.","volume":"346","author":"Goadsby","year":"2002","journal-title":"N Engl J Med"},{"issue":"9294","key":"zoi250999r9","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"zoi250999r10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1526-4610.1998.3801035.x","article-title":"Monitoring of acute migraine attacks: placebo response and safety data.","volume":"38","author":"Jhee","year":"1998","journal-title":"Headache"},{"issue":"1","key":"zoi250999r11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10194-007-0360-4","article-title":"Lessons from placebo effects in migraine treatment.","volume":"8","author":"Antonaci","year":"2007","journal-title":"J Headache Pain"},{"issue":"8","key":"zoi250999r12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/head.13907","article-title":"Efficacy and contextual (placebo) effects of CGRP antibodies for migraine: systematic review and meta-analysis.","volume":"60","author":"Forbes","year":"2020","journal-title":"Headache"},{"issue":"3","key":"zoi250999r13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1).","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"zoi250999r14","doi-asserted-by":"publisher","first-page":"m1668","DOI":"10.1136\/bmj.m1668","article-title":"Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice.","volume":"370","author":"Kaptchuk","year":"2020","journal-title":"BMJ"},{"key":"zoi250999r15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-34790-9","article-title":"A randomized controlled trial of effects of open-label placebo compared to double-blind placebo and treatment-as-usual on symptoms of allergic rhinitis.","author":"Schaefer","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"zoi250999r16","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1097\/j.pain.0000000000000700","article-title":"Open-label placebo treatment in chronic low back pain: a randomized controlled trial.","volume":"157","author":"Carvalho","year":"2016","journal-title":"Pain"},{"issue":"12","key":"zoi250999r17","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1097\/j.pain.0000000000001683","article-title":"Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial.","volume":"160","author":"Kleine-Borgmann","year":"2019","journal-title":"Pain"},{"issue":"1","key":"zoi250999r18","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1038\/s41598-018-20993-y","article-title":"Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial.","volume":"8","author":"Hoenemeyer","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"zoi250999r19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/oncolo\/oyac184","article-title":"Open-label placebo for the treatment of cancer-related fatigue in patients with advanced cancer: a randomized controlled trial.","volume":"27","author":"Yennurajalingam","year":"2022","journal-title":"Oncologist"},{"issue":"9","key":"zoi250999r20","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1097\/j.pain.0000000000002234","article-title":"Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial.","volume":"162","author":"Lembo","year":"2021","journal-title":"Pain"},{"issue":"1","key":"zoi250999r21","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1038\/s41598-021-83148-6","article-title":"Effects of open-label placebos in clinical trials: a systematic review and meta-analysis.","volume":"11","author":"von Wernsdorff","year":"2021","journal-title":"Sci Rep"},{"key":"zoi250999r22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006175","article-title":"Altered placebo and drug labeling changes the outcome of episodic migraine attacks.","author":"Kam-Hansen","year":"2014","journal-title":"Sci Transl Med"},{"issue":"5","key":"zoi250999r23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"zoi250999r24","journal-title":"JAMA"},{"issue":"6","key":"zoi250999r25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045969","article-title":"Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial.","volume":"11","author":"Schmidt","year":"2021","journal-title":"BMJ Open"},{"key":"zoi250999r26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"zoi250999r27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0304-3959(90)90068-O","article-title":"The Pain Disability Index: psychometric properties.","volume":"40","author":"Tait","year":"1990","journal-title":"Pain"},{"issue":"8","key":"zoi250999r28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","article-title":"A six-item short-form survey for measuring headache impact: the HIT-6.","volume":"12","author":"Kosinski","year":"2003","journal-title":"Qual Life Res"},{"issue":"2","key":"zoi250999r29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.pain.2010.02.043","article-title":"Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran.","volume":"149","author":"Geisser","year":"2010","journal-title":"Pain"},{"issue":"2","key":"zoi250999r30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/oxfordjournals.pubmed.a024606","article-title":"A shorter form health survey: can the SF-12 replicate results from the SF-36 in longitudinal studies?","volume":"19","author":"Jenkinson","year":"1997","journal-title":"J Public Health Med"},{"issue":"4","key":"zoi250999r31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/pds.2067","article-title":"Assessing general side effects in clinical trials: reference data from the general population.","volume":"20","author":"Rief","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"zoi250999r32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780140810","article-title":"The log transformation is special.","volume":"14","author":"Keene","year":"1995","journal-title":"Stat Med"},{"issue":"5","key":"zoi250999r33","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1097\/j.pain.0000000000002162","article-title":"Open-label placebo for chronic low back pain: a 5-year follow-up.","volume":"162","author":"Carvalho","year":"2021","journal-title":"Pain"},{"issue":"3","key":"zoi250999r34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/j.pain.0000000000002752","article-title":"No long-term effects after a 3-week open-label placebo treatment for chronic low back pain: a 3-year follow-up of a randomized controlled trial.","volume":"164","author":"Kleine-Borgmann","year":"2023","journal-title":"Pain"},{"issue":"1-2","key":"zoi250999r36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Core outcome measures for chronic pain clinical trials: IMMPACT recommendations.","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"issue":"5","key":"zoi250999r37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.55.5.629","article-title":"Migraine, quality of life, and depression: a population-based case-control study.","volume":"55","author":"Lipton","year":"2000","journal-title":"Neurology"},{"issue":"11","key":"zoi250999r38","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0895-4356(98)00109-7","article-title":"Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment.","volume":"51","author":"Gandek","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"zoi250999r39","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1097\/BRS.0000000000002298","article-title":"Minimal clinically important difference in quality of life for patients with low back Pain.","volume":"42","author":"D\u00edaz-Arribas","year":"2017","journal-title":"Spine (Phila Pa 1976)"},{"issue":"3","key":"zoi250999r40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","article-title":"Validation of the Headache Impact Test (HIT-6\u2122) across episodic and chronic migraine.","volume":"31","author":"Yang","year":"2011","journal-title":"Cephalalgia"},{"key":"zoi250999r41","author":"Tait","journal-title":"Arch Phys Med Rehabil"},{"key":"zoi250999r42","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-002-0050-0","author":"Rozen","year":"2002","journal-title":"Curr Treat Options Neurol"},{"issue":"10289","key":"zoi250999r43","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/S0140-6736(21)00392-5","article-title":"Nociplastic pain: towards an understanding of prevalent pain conditions.","volume":"397","author":"Fitzcharles","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"zoi250999r44","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1093\/abm\/kax057","article-title":"Open-label placebos for wound healing: a randomized controlled trial.","volume":"52","author":"Mathur","year":"2018","journal-title":"Ann Behav Med"},{"issue":"2","key":"zoi250999r45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jebm.12251","article-title":"Effects of placebos without deception compared with no treatment: a systematic review and meta-analysis.","volume":"10","author":"Charlesworth","year":"2017","journal-title":"J Evid Based Med"},{"key":"zoi250999r46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-39123-4","author":"Buergler","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"zoi250999r47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","article-title":"The pathophysiology of migraine: implications for clinical management.","volume":"17","author":"Charles","year":"2018","journal-title":"Lancet Neurol"},{"issue":"8","key":"zoi250999r48","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","article-title":"Migraine and the trigeminovascular system: 40 years and counting.","volume":"18","author":"Ashina","year":"2019","journal-title":"Lancet Neurol"},{"issue":"5472","key":"zoi250999r49","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1126\/science.288.5472.1765","article-title":"Neuronal plasticity: increasing the gain in pain.","volume":"288","author":"Woolf","year":"2000","journal-title":"Science"},{"issue":"2","key":"zoi250999r50","doi-asserted-by":"publisher","DOI":"10.1111\/jabr.12137","article-title":"The neurobiology of central sensitization.","volume":"23","author":"Harte","year":"2018","journal-title":"J Appl Biobehav Res"},{"key":"zoi250999r51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907805","author":"Colloca","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi250999r52","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11910-011-0245-4","article-title":"Nocebo in headaches: implications for clinical practice and trial design.","volume":"12","author":"Mitsikostas","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"13","key":"zoi250999r53","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1056\/NEJM196809262791304","article-title":"Adverse nondrug reactions.","volume":"279","author":"Reidenberg","year":"1968","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250999r54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/15265161.2011.652798","article-title":"To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent.","volume":"12","author":"Wells","year":"2012","journal-title":"Am J Bioeth"},{"issue":"1","key":"zoi250999r55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40359-022-00731-w","article-title":"Patients\u2019 experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study.","volume":"10","author":"Haas","year":"2022","journal-title":"BMC Psychol"},{"issue":"1572","key":"zoi250999r56","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1098\/rstb.2010.0385","article-title":"Placebo studies and ritual theory: a comparative analysis of Navajo, acupuncture and biomedical healing.","volume":"366","author":"Kaptchuk","year":"2011","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"1","key":"zoi250999r57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/jmp\/jhm005","article-title":"A phenomenology of the \u2018placebo effect\u2019: taking meaning from the mind to the body.","volume":"33","author":"Frenkel","year":"2008","journal-title":"J Med Philos"},{"key":"zoi250999r58","doi-asserted-by":"publisher","author":"Schaefer","journal-title":"Psychother Psychosomat","DOI":"10.1159\/000447242"},{"issue":"8","key":"zoi250999r59","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2021.06.024","article-title":"Primary and secondary outcome reporting in randomized trials: JACC State-of-the-Art Review.","volume":"78","author":"Pocock","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"zoi250999r35","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Rev. 1976","author":"Guy","year":"1976"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839764\/kleineborgmann_2025_oi_250999_1759324742.34183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:00:38Z","timestamp":1759935638000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839764"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.35739","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]}}}